Replies to post #130795 on Biotech Values

[turtlepower]

FOLD - I'm not too sure how reliable crowley is based on all the clinical milestones that have been missed but if the Amigal trial is positive he may look to sell the company. A potential catalyst this quarter is the ERT+Amigal PII interim trial results.

http://www.bloomberg.com/news/2010-12-22/amicus-open-to-future-glaxo-bid-if-fabry-drug-succeeds-in-study.html